SAN DIEGO -- (BUSINESS WIRE) -- Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced it has appointed Ardy Arianpour, MBA, as chief strategy officer. Based at Pathway Genomics’ San Diego headquarters, in this executive management position, Arianpour will spearhead the company’s global strategy, strategic planning, and lucrative partnerships for the company.
“Ardy is an industry expert and a highly respected leader with a wealth of deep experience in the biotechnology and personalized genomics space,” said Jim Plante, Pathway Genomics’ founder and CEO.
A seasoned business development veteran with more than 13 years of experience in the biotech industry, Arianpour has a distinguished track record of transforming startup companies into established and recognized multimillion-dollar enterprises. Most recently, he was the senior vice president of business development for Ambry Genetics and helped lead the company through a period of tremendous growth. Throughout his career, Arianpour has served in senior sales and business development roles, including for Clinical Data (acquired for $1.2 billion by Forest Laboratories), Cogenics (acquired by Beckman Coulter) and Eurogentec North America (acquired by Kaneka, a Japanese chemical company).
“Pathway Genomics is the future of genetic testing. Our vision is to expand and change clinical testing into broader markets worldwide and apply new technologies for faster medical and actionable results,” said Arianpour. “We are living in an era of personalized medicine and Pathway is poised to revolutionize genetic testing for every human in need.”
Arianpour holds a bachelor’s degree in biological sciences from the University of California, Irvine, and an MBA in strategic management from Marshall Goldsmith School of Management.
About Pathway Genomics Corporation
As a CAP-accredited and CLIA-certified clinical laboratory based in San Diego, California, Pathway Genomics provides physicians and their patients with actionable and accurate genetic information to improve or maintain health and wellness. Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation and commitment to medical responsibility – making it a leader in the commercial genetic testing industry. Pathway Genomics’ testing services cover a variety of conditions including cardiac health, cancer risk, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.